2014•Journal of Skin and Stem CellRequires access

Propranolol in Infantile Hemangioma: A Review Article

Parvin Mansouri, Somayeh Hejazi, Maryam Ranjbar, Safoura Shakoei

Open publisher page 3 citations

Abstract

Hemangioma is the most common benign cutaneous vascular tumor in infants and children. The Hemangioma incidence in the neonates is 2% to 3% that increases to 10% in those younger than one year of age. Before introduction of propranolol in 2008, different medications such as systemic corticosteroids and vincristine, with different side effects, were used for years. Since then, over 200 studies concerning propranolol administration have been published. This study reviews propranolol use in infantile hemangioma.

About this research paper

What this paper is about

Hemangioma is the most common benign cutaneous vascular tumor in infants and children. The Hemangioma incidence in the neonates is 2% to 3% that increases to 10% in those younger than one year of age. Before introduction of propranolol in 2008, different medications such as systemic corticosteroids and vincristine, with different side effects, were used for years. Since then, over 200 studies concerning propranolol administration have been published. This study reviews propranolol use in infantile hemangioma.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Hemangioma is the most common benign cutaneous vascular tumor in infants and children. The Hemangioma incidence in the neonates is 2% to 3% that increases to 10% in those younger than one year of age. Before introduction of propranolol in 2008, different medications such as systemic corticosteroids and vincristine, with different side effects, were used for years. Since then, over 200 studies concerning propranolol administration have been published. This study reviews propranolol use in infantile hemangioma.

Key concepts: Propranolol, Infantile hemangioma, Hemangioma, Medicine, Vascular Tumors, Vincristine, Vascular tumor, Incidence (geometry)

Related papers

Back to paper searchBrowse research topicsOriginal source
Propranolol in Infantile Hemangioma: A Review Article — Research Paper | ScholarLens